The Project
The project is funded by the European Union for three years and the Consortium includes 14 Scientific partners across Europe. The aim of the study is to identify the patient’s clinical and biological responses, novel “biomarkers” and tumour antigens which correlate with the failure to respond to immunotherapy. The research will also consider whether gender plays a role in determining the outcome of therapy.
Reports
The ENACT 12 month report can now be downloaded from the participants area.
ENACT Progress Meeting #3 - 27th September, Granada, Spain.
This meeting is to be held prior to PIVAC-6: 6th International Conference on Progress in Vaccination Against Cancer, 28th and 29th September 2006.
Hosted by Professor Federico Garrido (Partner No: 8)
To download agenda go to participants area
[ Back to top ]